What is the recommended dosing for Ofloxacin (Oflox)

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ofloxacin (Oflox) Dosing Recommendations

The standard recommended dosing for ofloxacin is 200-400 mg orally every 12 hours, with specific dosages varying based on the type of infection being treated. 1

Infection-Specific Dosing

Sexually Transmitted Infections

  • For nongonococcal cervicitis/urethritis due to C. trachomatis: 300 mg orally every 12 hours for 7 days 1
  • For mixed infection of the urethra and cervix due to C. trachomatis and N. gonorrhoeae: 300 mg orally every 12 hours for 7 days 1
  • For acute, uncomplicated urethral and cervical gonorrhea: 400 mg as a single dose 1
  • For nongonococcal urethritis: 300 mg orally twice daily for 7 days (alternative regimen) 2

Pelvic Inflammatory Disease

  • For acute pelvic inflammatory disease (oral treatment): 400 mg orally twice daily for 14 days 2
  • For parenteral treatment: 400 mg IV every 12 hours, typically with metronidazole 500 mg IV every 8 hours 2

Urinary Tract Infections

  • For uncomplicated cystitis due to E. coli or K. pneumoniae: 200 mg orally every 12 hours for 3 days 1
  • For uncomplicated cystitis due to other approved pathogens: 200 mg orally every 12 hours for 7 days 1
  • For complicated UTIs: 200 mg orally every 12 hours for 10 days 1
  • For prostatitis due to E. coli: 300 mg orally every 12 hours for 6 weeks 1

Respiratory Infections

  • For acute bacterial exacerbation of chronic bronchitis: 400 mg orally every 12 hours for 10 days 1
  • For community-acquired pneumonia: 400 mg orally every 12 hours for 10 days 1

Skin and Skin Structure Infections

  • For uncomplicated skin and skin structure infections: 400 mg orally every 12 hours for 10 days 1

Special Dosing Considerations

Renal Impairment

  • For patients with creatinine clearance 20-50 mL/min: maintain usual dose but extend interval to every 24 hours 1
  • For patients with creatinine clearance <20 mL/min: reduce dose by 50% and administer every 24 hours 1

Hepatic Impairment

  • For patients with severe liver function disorders (e.g., cirrhosis with or without ascites): maximum daily dose should not exceed 400 mg 1

Administration Considerations

  • Antacids containing calcium, magnesium, or aluminum; sucralfate; divalent or trivalent cations such as iron; multivitamins containing zinc; or didanosine should not be taken within 2 hours before or after taking ofloxacin 1
  • Ofloxacin has almost complete bioavailability (95-100%), with peak serum concentrations of 2-3 mg/L after a 400mg oral dose 3
  • The average half-life is 5-8 hours, with elimination highly dependent on renal clearance 3

Clinical Efficacy

  • Ofloxacin has demonstrated efficacy in various infections with response rates ranging from 70-91% in clinical trials 4, 5
  • For respiratory infections, efficacy rates of approximately 80.7% have been reported 6
  • In complicated urinary tract infections, excellent to moderate responses were observed in 91% of patients after 14 days of treatment 4

Common Pitfalls and Caveats

  • When treating PID, ofloxacin lacks adequate anaerobic coverage; consider adding metronidazole for complete coverage 2
  • Resistance during therapy may develop, particularly with Pseudomonas aeruginosa (reported rate of 17.9%) 5
  • Monitor for adverse effects, which may include gastrointestinal disturbances (4.5%), hypersensitivity reactions (0.5%), and central nervous system effects such as dizziness (2.3%) 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Ofloxacin clinical pharmacokinetics.

Clinical pharmacokinetics, 1992

Research

[Clinical study of ofloxacin in complicated urinary tract infection].

Hinyokika kiyo. Acta urologica Japonica, 1988

Research

Clinical experience with parenteral and oral ofloxacin in severe infections.

Scandinavian journal of infectious diseases. Supplementum, 1990

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.